menu
    • menu
    [{"orgOrder":0,"company":"Enteris Biopharma Inc","sponsor":"CARA Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Licensing Agreement","leadProduct":"Difelikefalin","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Enteris Biopharma Inc","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0.029999999999999999,"dosageForm":"Tablet","sponsorNew":"Enteris Biopharma Inc \/ Cara Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Enteris Biopharma Inc \/ Cara Therapeutics"},{"orgOrder":0,"company":"Enteris Biopharma Inc","sponsor":"CARA Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Licensing Agreement","leadProduct":"Difelikefalin","moa":"Kappa opioid receptor","graph1":"Nephrology","graph2":"Phase II","graph3":"Enteris Biopharma Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Enteris Biopharma Inc \/ Cara Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Enteris Biopharma Inc \/ Cara Therapeutics"},{"orgOrder":0,"company":"Enteris Biopharma Inc","sponsor":"CARA Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Licensing Agreement","leadProduct":"Difelikefalin","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Enteris Biopharma Inc","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0.029999999999999999,"dosageForm":"Tablet","sponsorNew":"Enteris Biopharma Inc \/ Cara Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Enteris Biopharma Inc \/ Cara Therapeutics"},{"orgOrder":0,"company":"Enteris Biopharma Inc","sponsor":"SWK Holdings","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Leuprolide Acetate","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Enteris Biopharma Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Enteris Biopharma Inc \/ SWK Holdings","highestDevelopmentStatusID":"8","companyTruncated":"Enteris Biopharma Inc \/ SWK Holdings"},{"orgOrder":0,"company":"Enteris Biopharma Inc","sponsor":"CARA Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Licensing Agreement","leadProduct":"Difelikefalin","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Enteris Biopharma Inc","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0.050000000000000003,"dosageForm":"Tablet","sponsorNew":"Enteris Biopharma Inc \/ Cara Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Enteris Biopharma Inc \/ Cara Therapeutics"},{"orgOrder":0,"company":"Enteris Biopharma Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Leuprolide Acetate","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Enteris Biopharma Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Enteris Biopharma Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Enteris Biopharma Inc \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Enteris Biopharma Inc

    Menu

    Enteris Biopharma Inc

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    EXCIPIENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Enteris Biopharma Inc

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Enteris Biopharma Inc

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Leuprolide Acetate

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Enteris BioPharma Presents Study of Ovarest® Demonstrating Oral Delivery Comparable to or Exceeding Injectabl...

                            Details : Ovarest® (leuprolide) is a gonadotropin-releasing hormone analogue that is used to treat endometriosis and uterine fibroids in women, prostate cancer in men, and central precocious puberty in boys and girls.

                            Brand Name : Ovarest

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            October 26, 2022

                            Lead Product(s) : Leuprolide Acetate

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Enteris Biopharma Inc

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Enteris Biopharma Inc

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Difelikefalin

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : CARA Therapeutics

                            Deal Size : $46.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            SWK Holdings' Subsidiary, Enteris BioPharma, Receives $5 Million Milestone Payment from Cara Therapeutics

                            Details : The milestone payment is related to continued clinical progress of Oral KORSUVA (difelikefalin), which is currently the subject of four separate clinical programs for pruritus in patients with hepatic impairment due to primary biliary cholangitis.

                            Brand Name : Korsuva

                            Molecule Type : Peptide

                            Upfront Cash : $8.0 million

                            October 10, 2022

                            Lead Product(s) : Difelikefalin

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : CARA Therapeutics

                            Deal Size : $46.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Enteris Biopharma Inc

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Enteris Biopharma Inc

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Leuprolide Acetate

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Phase II

                            Sponsor : SWK Holdings

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Enteris BioPharma Announces Acceptance of Abstract for Oral Presentation at ASRM 2022 Scientific Congress & Ex...

                            Details : Oral administration of Ovarest (leuprolide) offers the potential to better address diseases in which gonadotropin-releasing hormone (GnRH) agonists are known to provide benefit and for which an oral format can improve patient compliance.

                            Brand Name : Ovarest

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            July 14, 2022

                            Lead Product(s) : Leuprolide Acetate

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Phase II

                            Sponsor : SWK Holdings

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Enteris Biopharma Inc

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Enteris Biopharma Inc

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Difelikefalin

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : CARA Therapeutics

                            Deal Size : $25.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            SWK Holdings' Subsidiary, Enteris BioPharma, Receives $5 Million Milestone Payment from Cara Therapeutics

                            Details : Enteris is eligible to receive additional potential milestone payments over the next several quarters, subject to the achievement of certain development milestones for Oral KORSUVA, of which Enteris will retain half.

                            Brand Name : Korsuva

                            Molecule Type : Peptide

                            Upfront Cash : $5.0 million

                            December 09, 2021

                            Lead Product(s) : Difelikefalin

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : CARA Therapeutics

                            Deal Size : $25.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Enteris Biopharma Inc

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Enteris Biopharma Inc

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Difelikefalin

                            Therapeutic Area : Nephrology

                            Study Phase : Phase II

                            Sponsor : CARA Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            SWK Holdings' Subsidiary, Enteris BioPharma, Receives $10 Million Milestone Payment from Cara Therapeutics

                            Details : This milestone payment was triggered by confirmation from Cara of the completion of an End-of-Phase 2 Meeting with the U.S. Food and Drug Administration (FDA) for Oral KORSUVA in patients with non-dialysis dependent (NDD) chronic kidney disease (CKD-aP).

                            Brand Name : Korsuva

                            Molecule Type : Peptide

                            Upfront Cash : $8.0 million

                            June 11, 2021

                            Lead Product(s) : Difelikefalin

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase II

                            Sponsor : CARA Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Enteris Biopharma Inc

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Enteris Biopharma Inc

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Difelikefalin

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : CARA Therapeutics

                            Deal Size : $13.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            SWK Holdings’ Subsidiary, Enteris Biopharma, Receives Second Milestone Payment from Cara Therapeutics

                            Details : Enteris BioPharma, received a second milestone payment from Cara Therapeutics (Nasdaq: CARA) related to the license agreement for Peptelligence oral formulation technology utilized in Oral KORSUVA, the oral formulation of Cara’s first-in-class KOR agon...

                            Brand Name : Korsuva

                            Molecule Type : Peptide

                            Upfront Cash : $8.0 million

                            December 24, 2020

                            Lead Product(s) : Difelikefalin

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : CARA Therapeutics

                            Deal Size : $13.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth